A Trial Comparing Pharmacokinetics, Safety and Tolerability of Two Subcutaneous Concentrations of Dapiglutide

2024-516901-21-00 Protocol ZP7570-24026 Human pharmacology (Phase I) - Other Ended

Start 23 Dec 2024 · End 25 Apr 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol ZP7570-24026

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 34
Countries 1
Sites 1

Weight management

Key facts

Sponsor
Zealand Pharma A/S
Participant type
Patients
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nutritional and Metabolic Diseases [C18]
Trial duration
23 Dec 2024 → 25 Apr 2025
Decision date (initial)
2024-12-10
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Weight management

VersionLevelCodeTermSystem organ class
20.1 LLT 10013225 Disorder gastrointestinal 10017947

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Zealand Pharma A/S

Sponsor organisation
Zealand Pharma A/S
Address
Sydmarken 11
City
Soeborg
Postcode
2860
Country
Denmark

Scientific contact point

Organisation
Zealand Pharma A/S
Contact name
Clinical Trial Information Desk

Public contact point

Organisation
Zealand Pharma A/S
Contact name
Clinical Trial Information Desk

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 34 1
Rest of world 0

Investigational sites

Germany

1 site · Ended
PROFIL Institut fuer Stoffwechselforschung GmbH
n/a, Hellersbergstrasse 9, Hammfeld, Neuss

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2024-12-23 2025-04-25 2024-12-23 2025-03-16

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-10-11 Germany Acceptable
2024-12-06
2024-12-10
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-01-23 Germany Acceptable
2024-12-06
2025-01-23
3 NON SUBSTANTIAL MODIFICATION NSM-2 2025-04-09 Germany Acceptable
2024-12-06
2025-04-09